Overview
Mark is a Counsel in Linklaters’ Antitrust & Foreign Investment Group, with extensive experience advising clients on a variety of complex merger control, foreign investment and regulatory matters. Mark advises on a range of antitrust and foreign investment matters across all sectors, with particular experience in the healthcare, utilities, telecommunications and pharmaceutical sectors.
Mark’s key clients include: Novo Holdings, Brookfield, Northern Gas Networks, Thames Water, Novonesis, Arqiva, National Grid.
Work highlights
- Novo Holdings: advising on the merger control, foreign investment and foreign subsidies aspects of its proposed $16.5bn acquisition of Catalent, a global contract development and manufacturing organisation.
- Bharti Global on its proposed acquisition of a c.24.5% stake in BT Group plc from Altice UK S à.r.l. including on the foreign investment filings relating to such acquisition.
- Brookfield: advising on the merger control filings associated with its £2.2 billion acquisition of Network International Holdings plc.
- Novo Holdings: on the merger control and FDI aspects of its investment in Single Use Support, a fast-growing Austria-based life science tools company providing advanced technology solutions for the pharmaceutical production process.
- Novozymes: advising on the merger control and FDI filings in connection with its statutory merger with Chr. Hansen Holding A/S.
- Northern Gas Networks: on its appeal to the CMA in relation to the RIIO-GD2 price control.
Education and qualifications
Mark holds a BA (Hons) in History from the University of Cambridge.
